Correlation Between Crispr Therapeutics and Molecular Partners
Can any of the company-specific risk be diversified away by investing in both Crispr Therapeutics and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crispr Therapeutics and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Crispr Therapeutics AG and Molecular Partners AG, you can compare the effects of market volatilities on Crispr Therapeutics and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crispr Therapeutics with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crispr Therapeutics and Molecular Partners.
Diversification Opportunities for Crispr Therapeutics and Molecular Partners
-0.64 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Crispr and Molecular is -0.64. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Crispr Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crispr Therapeutics AG are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Crispr Therapeutics i.e., Crispr Therapeutics and Molecular Partners go up and down completely randomly.
Pair Corralation between Crispr Therapeutics and Molecular Partners
Given the investment horizon of 90 days Crispr Therapeutics AG is expected to generate 1.95 times more return on investment than Molecular Partners. However, Crispr Therapeutics is 1.95 times more volatile than Molecular Partners AG. It trades about 0.39 of its potential returns per unit of risk. Molecular Partners AG is currently generating about -0.13 per unit of risk. If you would invest 4,425 in Crispr Therapeutics AG on April 20, 2025 and sell it today you would earn a total of 2,088 from holding Crispr Therapeutics AG or generate 47.19% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Crispr Therapeutics AG vs. Molecular Partners AG
Performance |
| Timeline |
| Crispr Therapeutics |
| Molecular Partners |
Crispr Therapeutics and Molecular Partners Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Crispr Therapeutics and Molecular Partners
The main advantage of trading using opposite Crispr Therapeutics and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crispr Therapeutics position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.| Crispr Therapeutics vs. Intellia Therapeutics | Crispr Therapeutics vs. Editas Medicine | Crispr Therapeutics vs. Vertex Pharmaceuticals | Crispr Therapeutics vs. Beam Therapeutics |
| Molecular Partners vs. Mineralys Therapeutics, Common | Molecular Partners vs. AN2 Therapeutics | Molecular Partners vs. Pharvaris BV | Molecular Partners vs. PepGen |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Complementary Tools
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |